Technical Conference:
13 – 18 May 2018
15 – 17 May 2018

Technology Transfer Abstracts


Tutorial Abstracts:

Lasers and Optics Technology Transfer at LLNL
Presented by: David Dawes, Business Development Executive, Innovation and Partnerships Office, Lawrence Livermore National Laboratory, Livermore, CA, USA

While fulfilling the lab’s national security, stockpile stewardship and safety mission, inventive researchers often conceive novel dual-use solutions to industry challenges. The Innovation and Partnerships Office at LLNL has a long history helping lab researchers engage and partner with industry. Success stories include: Large Scale Computing and CAD design of integrated circuits, Digital Globe the basis of Google Earth, and Laser Shot Peening for strengthening critical aircraft components against fatigue failure. In addition to furthering fundamental laser technology, more recent developments at the lab are benefiting diverse industries including: medical imaging, additive manufacturing, telecommunications, defense and advanced materials processing. Examples of these newer developments and future trends will be reviewed.


Pitch Panel Abstracts:

Skin-like Flexible Full-Color Plasmonic Displays
Presented by: Debashis Chanda, Chief Scientific Officer, e-skin Displays, Inc. USA

The talk will focus on enhanced light-latter interactions on nanostructured surfaces for plasmonic full-color displays on flexible substrates. The newly developed printing techniques enable large area printing of such nanostructured surfaces for low cost manufacturing.

3D Imaging Beyond the Diffraction Limit
Presented by: Leslie Kimerling, Co-Founder & CEO, Double Helix, USA 

Until recently optical imaging at the cellular level has been limited by Abbe’s Diffraction Limit of Light (~200 nm).  The study of cellular structures at the molecular level required use of x-ray or electron microscopy and with it the need to freeze the sample preventing live imaging.  With Double Helix’s Light EngineeringTM technology, scientists can now see and track activity with a 10x improvement in imaging precision (~25 nm) and unprecedented 3D depth range, enabling work with cells at the molecular level for both disease and drug discovery. 

Emerging Applications for Single Crystal CVD Diamond
Presented by: Alexander Muhr, Senior Applications Engineer, Element Six, USA 

Microwave plasma chemical vapour deposition (CVD) of diamond has enabled a multitude of optical applications due to its range of extreme properties. Transparency from the ultra-violet to the infra-red is complemented by the highest thermal conductivity of any bulk material, high laser damage threshold, low thermal expansion and chemical inertness.  Element Six will review and summarize key progress made in state of the art diamond for a number of case studies, including high power laser optics, cooling in high power disk lasers, diamond raman lasers and quantum photonics applications.

Noninvasix, Inc.
Presented by: Graham Randall, CEO, Noninvasix, Inc., USA 

To reduce the incidence of neonatal mortality and morbidity, Noninvasix is developing a patient monitor to directly, accurately, and noninvasively measure brain oxygenation in preterm and low birth weight babies in the neonatal intensive care unit. 

With patented optoacoustic technology at its core, Noninvasix’s system pulses laser light into the brain to directly measure the amount of oxygen the baby is receiving in real time.  Prompt recognition of low cerebral venous oxygenation can be used to guide therapeutic interventions and reduce adverse outcomes.

In contrast to other purely spectroscopic techniques, such as near-infrared spectroscopy, this technology provides an absolute, rather than relative measurement, and can be targeted to specific blood vessels.

Noninvasix recently completed its third-generation clinical prototype, which has been tested in both fetuses and neonates in the delivery room and NICU at University of Texas Medical Branch in Galveston. The company’s next step is to build a manufacturing prototype, which will be used in clinical trials and the FDA for regulatory clearance.  FDA 510(k) clearance is expected in 2019.

Sponsored by: